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Introduction 
Aortic replacement using cadaveric arterial allografts 
was introduced by Carrel in 1912.1 This was the first 
material used for arterial reconstruction i vascular 
surgery, but its use was associated with late de- 
generative phenomena (dilatation, calcification, throm- 
bosis). During the 1960s arterial allografts fell into 
disuse due to the development of synthetic prostheses 
characterised by good long-term stability. 2 The use of 
aortic prostheses rapidly became the standard solution 
in vascular surgery, even if its use was associated 
with a risk of infection, a rare but life-threatening 
complication wlnich develops in 1-6%. 3 The treatment 
of aortic infected prostheses requires its surgical re- 
moval and revascularisation f ischaemic areas is sub- 
sequently obtained using different procedures. One of 
these, recently assessed at different European centres, 
consists in in situ replacement of the removed pros- 
theses with cadaveric arterial allografts. The rationale 
of this procedure originates from cardiac surgery, in 
which it has been clearly demonstrated that allografts 
offer good resistance to infection in the treatment 
of aortic valve endocarditis. 4 Allograft resistance to 
infection was documented by Kieffer et al., who has 
employed aortofemoral llografts in the treatment of 
abdominal aortic infected prostheses since 1988. 5The 
renewed interest in human vascular grafts leads us to 
an obvious historical comparison: what has changed 
from the experience of Carrel to the present op- 
portunities in the field of transplantation? Two aspects 
must be considered: (a) advances in tissue banking 
technology can supply surgeons with tissues of high 
quality and safety and (b) the awareness that AIDS 
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and other diseases can be transmitted to the recipients 
with tissues from cadaveric or living donors. 
In this paper we report the experience of the Col- 
laborative Vascular Homograft Group (CVHG), which 
was established with the aim of supplying vascular 
homografts certified for safety and quality for the 
treatment of infected aortic prostheses. 
Materials and Methods 
This programme was organised in close co-operation 
between the Reference Centre (RC) of the North Italy 
Transplant programme (NITp), six departments of 
vascular surgery and a homograft bank (HB). NITp is a 
transplant organisation which has co-ordinated organ 
procurement and transplantation activity since 1976, 
and at present serves an area of about 18 million 
inhabitants. Since 1993 the NITp RC has developed 
facilities aimed at satisfying the increasing demand 
for human tissues. During 1994 surgeons from the 
above mentioned vascular surgery departments met 
at NITp's RC to define common operative protocols, 
characterised by the following criteria: (a) infection of 
abdominal aortic prostheses was the only indication 
for aortic grafting; (b) NITp multiorgan donors were 
the source for arterial allografts retrieved at the pro- 
curing centres (PC); (c) only transplant centres (TC) 
authorised by the Ministry of Health could perform 
vessel retrieval and transplantation; (d) before the HB 
was activated in January 1995, fresh allografts were 
used. The tasks of each operative unit are summarised 
as follows: 
1. Procuring centres: evaluate all potential organ/tis- 
sue donors, retrieve arteries, report data on donor 
and tissues to RC. 
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2. Homograft bank: processes, cryopreserves, dis- 
tributes and certifies homograft quality according 
to standard operating procedures. 6 
3. Transplant centres: evaluate recipient, perform aor- 
tic transplantation and post-transplant follow-up. 
4. Reference centre: collects data, co-ordinates tissue 
and organ procurement, allocates grafts, analyses 
post-transplant data; manages a quality im- 
provement programme. 
For our programme we adopted a "three level or- 
ganisational model": (1) RC co-ordinates all steps from 
potential donor to transplantation, (2) HB is re- 
sponsible for tissue quality and safety and (3) PC are 
responsible for donor quality and safety, and TC for 
recipient evaluation and transplantation. 
Donor exclusion criteria 
These are the same as adopted in NITp for organ 
donors and are also recommended by the European 
General Standards for Tissue Banking7: presence of 
risk factors for HIV/hepatitis (and other transmittable 
diseases) in donor history; actual signs or symptoms of 
transmittable diseases (including malignancies); donor 
serology positive for one of the following tests: anti- 
HIV1,2, HBsAg, anti-HCV, syphilis. 
Allograft harvesting and banking 
Vessel harvesting is performed after organ retrieval, 
according to the CVHG protocol. Aortic sections re- 
trieved were: thoracic aorta, the abdominoaortic-iliac 
tract and the femoral (deep and superficial) arterial 
tract. For each donor all aortic vessels harvested were 
put into a sterile bag containing Eurocollins (500 ml), 
heparin, antibiotics. Vessels were kept at 4°C and 
transported within 12 h to the HB. All vessels ent to 
the HB were processed according to standard op- 
erating procedures. The following steps were carried 
out: macroscopic vessel evaluation and classification; 
histological evaluation of small samples (1-2 cm 2) isol- 
ated from wall vessels; storage at 4 °C for 96 h, and 
decontamination with a low-dose antibiotic solution; 
cryopreservation i nitrogen liquid/vapour phase 
with 100 ml of a solution composed of RPMI, 10% 
dimethysulphoxide (DMSO), 10% fetal calf serum: a 
cooling rate of l°C/min was obtained using an auto- 
matically controlled freezing cycle (in order to preserve 
cell viability); distribution to the TC of the vessels 
allocated by RC. Vessels were quarantined for at least 
50 days before distribution: vessel samples were cul- 
tured for bacterial/fungal contamination after each 
operative step. Tissues were discharged when con- 
taminated or when classified in the anatomical class = 
1 (aneurysms, wall calcifications >50%, intimal ul- 
cerations). 
Results 
Allograft donors 
During the period March 1994-November 1995, 142 
aortic tracts were retrieved from 49 donors: 43 thoracic 
aortas, 31 abdominal aortas, 48 aortoiliac-femoral 
tracts, 20 superficial femoral arteries. In 29 cases it was 
possible to retrieve the whole aortic carrefour: for the 
remaining 20 donors the carrefour was not retrieved 
as a whole, because of the possible use of iliac-aorta s 
free-graft in liver transplantation, or due to abdominal 
aortic incannulation to perform perfusion. The donors' 
median age was 43 years (range 19-63). Regarding 
anatomical class, 60% of thoracic aortas, 73% of ab- 
dominal aortas and 75% of superficial femoral arteries 
were classified as class III (absence of arterial esions). 
Out of 142 vessels, 98 were sent to the HB for pro- 
cessing whereas of the remaining 44, 40 were trans- 
planted as fresh homografts. The vessel discard rate 
at the HB was 10% (because of anatomical ab- 
normalities and bacterial/fungal contamination). 
Patients 
During the period March 1994-September 1995, 37 
patients, all with infected abdominal aortic prosthesis, 
were evaluated at six different TCs according to a 
common protocol. Cases complicated by aortoenteric 
fistulas were given priority. Out of 37 recipients who 
entered the waiting list, four were very urgent: TCs 
asked for an allograft which was to be transplanted 
within 24-72 h; for 26 recipients an allograft was re- 
quested 1-3 weeks before surgery. Of the remaining 
seven patients registered at RC, five were treated with 
surgical solution other than transplantation and two 
died before undergoing transplantation due to wor- 
sening of their clinical conditions. The median recipient 
age was 67 years (range 51-77), 26 were male and six 
female. 
During the above mentioned period, 24 patients 
were grafted at five different TCs. The surgical pro- 
cedure consisted in removal of the former infected 
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graft and its replacement in situ with the allograft. The 
patients were administered antibiotic therapy for at 
least 1 month following transplantation, on the basis 
of bacterial cultures performed on infected prostheses 
samples. The number  of transplants performed by 
each TC were, respectively, 13, 4, 3, 3 and 1. Eighteen 
out of 24 recipients are still alive after a median 
follow-up of 9 months (range 1-20). One case of leg 
amputat ion (4.5%) and three cases of graft failure 
(12.5%) (one graft rupture, one dilatation, one throm- 
botic occlusion) occurred. Three patients died within 
30 days from transplantation (acute mortality rate = 
12.5%); in three recipients death occurred after 2, 3 and 
13 months, respectively, due to non-vascular causes. 
Twelve patients received fresh homografts, 12 were 
treated with cryopreserved homografts: no differences 
in terms of graft survival were observed between the 
two groups. All surviving patients recovered from 
infection at 3 months follow-up, as defined by clinical 
and instrumental evaluation (CT scanning, scin- 
tigraphic evaluation by marked leukocytes and colour 
Doppler). 
Discussion 
Our experience is prel iminary but seems to confirm 
that aortic allografts may be used as a bridge to 
prosthetic replacement, and that this procedure might 
also prove a long-term solution. The increasing number  
of treated cases will allow us to compare fresh vs. 
cryopreserved homografts. Vascular surgery centres 
interested in allografts are increasing, and CVHG facil- 
ities, in agreement with NITp philosophy, will be 
extended to other Italian regions. The organisational 
model  yielded good results, co-operation with organ 
harvesting teams is satisfactory, and in the near future 
we will extend vessel retrieval to non-heart beating 
tissue donors, thus maximising vessel retrieval, espe- 
cially at the aortic bifurcation level. 
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